GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (STU:45O) » Definitions » Deferred Policy Acquisition Costs

Orgenesis (STU:45O) Deferred Policy Acquisition Costs


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Orgenesis (STU:45O) Business Description

Industry
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.